PDF(Pubmed)
Abstract：
Angiogenic inhibitors have been demonstrated to inhibit tumour cells in ovarian carcinoma, but the initial data are not accurate enough to indicate the influence of these drugs on the post-therapy wound healing. In order to assess the effect of angiogenic inhibitors on the treatment of wound healing in ovarian carcinoma, we performed a meta-analysis of related literature. For this meta-analysis, we looked up the data from 4 databases: PubMed, EMBASE, Web of Science and the Cochrane Library. All literature searches were performed up to October 2023. The ROBINS-I tool was applied to evaluate the risk of bias in the inclusion trials, and statistical analysis was performed with RevMan 5.3. In this research, 971 related research were chosen, and 9 of them were selected. These studies were published between 2013 and 2023. In all 9 trials, a total of 3902 patients were enrolled. There was a significant reduction in the risk of wound infection in the control group than in those who received angiogenesis inhibitors (OR, 0.66; 95% CI, 0.49-0.89 p = 0.007). The risk of developing an abscess was not significantly different from that of those who received angiogenesis inhibitors (OR, 0.80; 95% CI, 0.20-3.12 p = 0.74). The risk of perforation in the control group was smaller than that in those receiving angiogenic inhibitors (OR, 0.25; 95% CI, 0.11-0.56 p = 0.0006). There was a significant increase in the risk of injury and GI perforation in women who received angiogenic inhibitors than in the control group. But the incidence of abscess did not differ significantly among the two groups.
摘要：
血管生成抑制剂已被证明可以抑制卵巢癌中的肿瘤细胞，但初始数据不够准确，不足以表明这些药物对治疗后伤口愈合的影响。为了评估血管生成抑制剂对卵巢癌伤口愈合的治疗效果，我们对相关文献进行了荟萃分析.对于这个荟萃分析，我们查阅了4个数据库的数据：PubMed,EMBASE,WebofScience和Cochrane图书馆。所有文献检索都进行到2023年10月。ROBINS-I工具用于评估纳入试验中的偏倚风险，采用RevMan5.3进行统计学分析。在这项研究中,选择了971项相关研究，其中9人被选中。这些研究发表于2013年至2023年之间。在所有9项试验中，共纳入3902例患者.与接受血管生成抑制剂的对照组相比，对照组的伤口感染风险显着降低（OR，0.66；95%CI，0.49-0.89p=0.007）。患脓肿的风险与接受血管生成抑制剂的患者没有显着差异（OR，0.80；95%CI，0.20-3.12p=0.74）。对照组的穿孔风险小于接受血管生成抑制剂的患者（OR，0.25；95%CI，0.11-0.56p=0.0006）。与对照组相比，接受血管生成抑制剂的女性受伤和胃肠道穿孔的风险显着增加。但两组脓肿发生率无明显差异。
